| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 07/15/2008 | CA2271857C Method for treating symptoms of diabetes |
| 07/15/2008 | CA2225398C Pharmaceutical composition comprising albumin as an active ingredient |
| 07/10/2008 | WO2008083256A2 Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof |
| 07/10/2008 | WO2008082948A2 Ophthalmic alginate composition related methods of manufacture and methods of use |
| 07/10/2008 | WO2008080939A1 Isosorbide mononitrate derivatives for the treatment of ocular hypertension |
| 07/10/2008 | WO2008064039A3 Prostaglandin prodrugs as ocular hypotensive agents |
| 07/10/2008 | WO2008021975A3 Therapeutic lactams |
| 07/10/2008 | US20080167600 Device for delivery of an agent to the eye and other sites |
| 07/10/2008 | US20080167384 Adding to food or beverage; all forms of retinitis pigmentosa, night blindness |
| 07/10/2008 | US20080167362 Time-release tablets or capsules also containing an opoid or analgesic; cyclooxygenase-2 inhibitors |
| 07/10/2008 | US20080167345 Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
| 07/10/2008 | US20080167331 Lowering intraocular pressure; glaucoma |
| 07/10/2008 | US20080167311 Glaucome therapy; vision defects |
| 07/10/2008 | US20080167281 Benzocaine, antipyrine, aluminum acetate, acetic acid, and optionally a polycosanol such as 1-nonacosanol, an antiinflammatory agent, and/or aloe; free of cyclooxygenase-2 inhibitors |
| 07/10/2008 | US20080167248 Anti-Aging Effects Of Substance P |
| 07/10/2008 | US20080167246 Ophthalmic and Contact Lens Solutions Containing Peptides as Preservative |
| 07/10/2008 | US20080167227 biodrug laminin protein as angiogenesis inhibitors, antitumor agents; Inducing apoptosis in tissues; binding antibodies |
| 07/10/2008 | US20080166436 Cold pressed citrus oils and deionized water; cleaning ear canals of mammalian animals; safely removing debris, excess ear wax, parasites and microbes |
| 07/10/2008 | US20080166387 Anti-angiogenic compositions and methods of use |
| 07/10/2008 | CA2674144A1 Isosorbide mononitrate derivatives for the treatment of ocular hypertension |
| 07/09/2008 | EP1942187A1 Cytokine protein family |
| 07/09/2008 | EP1941876A1 Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension |
| 07/09/2008 | EP1941829A2 Noninvasive measurement of chemical substances |
| 07/09/2008 | EP1940471A1 IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
| 07/09/2008 | EP1940381A1 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate |
| 07/09/2008 | EP1940370A2 Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity |
| 07/09/2008 | EP1940353A2 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis |
| 07/09/2008 | EP1784164A4 Methods for transmembrane treatment and prevention of otitis media |
| 07/09/2008 | EP1583551A4 Composition for preventing the formation of new scar comprising bmp-7 |
| 07/09/2008 | EP1303490B1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 07/09/2008 | EP1303304B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 07/09/2008 | EP1234185B1 Pin1 as a marker of the stage of agressiveness and/or metastasis of abnormal cell growth |
| 07/09/2008 | EP1156820B1 Use of vascular endothelial growth factor-2 (vegf-2) |
| 07/09/2008 | EP1058680B1 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists |
| 07/09/2008 | CN101217948A Percutaneously absorptive ophthalmic preparation comprising epinastine |
| 07/09/2008 | CN101214287A Medicament for treating otitis medis |
| 07/09/2008 | CN101214246A Palmatine nano particle preparations and preparation thereof |
| 07/09/2008 | CN101214232A Lutein micropills and preparation thereof |
| 07/09/2008 | CN101214217A Hydrogel-hydrogel composite material and preparation thereof and use of medicament sustained-release matrix |
| 07/09/2008 | CN100400504C Amide derivatives as inhibitors of the enzymatic activity of renin |
| 07/09/2008 | CN100400487C Glucocorticoid receptor modulators |
| 07/09/2008 | CN100400100C Methods for preventing or attenuating patthoangiogenic conditions |
| 07/09/2008 | CN100400096C Reduced glutathione eye medicinal preparation |
| 07/09/2008 | CN100400080C Compositions for treating and/or preventing pollinosis |
| 07/09/2008 | CN100400038C Compound soft lutein capsule and its preparing process |
| 07/08/2008 | US7396946 Compound for treatment of external secretion disorders |
| 07/08/2008 | US7396843 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/08/2008 | US7396831 Vanilloid receptor ligands and their use in treatments |
| 07/08/2008 | US7396663 Isolated polynucleotide encoding a G-protein coupled receptor |
| 07/08/2008 | CA2445620C Tetracyclic compounds as pde5-inhibitors |
| 07/08/2008 | CA1341576C Diagnosis of retinoblastoma |
| 07/03/2008 | WO2008080110A1 Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
| 07/03/2008 | WO2008079980A1 Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| 07/03/2008 | WO2008079880A1 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of glaucoma and ocular hypertension |
| 07/03/2008 | WO2008079783A1 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 07/03/2008 | WO2008079697A2 Method of treating mucin deficiency with an active pharmaceutical and related composition |
| 07/03/2008 | WO2008078762A1 Novel n-(2-aminophenyl)benzamide derivative having an urea structure |
| 07/03/2008 | WO2008078411A1 Pharmaceutical agent for prevention and/or treatment of inflammatory myopathy |
| 07/03/2008 | WO2008078095A1 Treatment of macular degeneration |
| 07/03/2008 | WO2008054594A3 Method for controlling angiogenesis in animals |
| 07/03/2008 | WO2008049919A3 Rho kinase inhibitors |
| 07/03/2008 | WO2007149728A3 Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| 07/03/2008 | WO2007098122A3 Methods for the treatment of macular degeneration and related eye conditions |
| 07/03/2008 | US20080161402 Targeting the Reverse Mode of the Na+/Ca2+ Exchanger For the Treatment of Neurodegenerative Conditions |
| 07/03/2008 | US20080161297 Rho kinase inhibitors |
| 07/03/2008 | US20080161270 Angiogenesis inhibitors |
| 07/03/2008 | US20080161266 Aqueous solution of alginate having guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units and a cationic antimicrobial agent; forms less deactivating complexes with cationic antimicrobial agent |
| 07/03/2008 | US20080161250 Topical treatment or prevention of ocular infections |
| 07/03/2008 | US20080161226 Activatable Clostridial Toxins |
| 07/03/2008 | US20080160576 Anti-alphabeta3 humanized monoclonal antibodies |
| 07/03/2008 | US20080160034 Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| 07/03/2008 | US20080160022 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 07/03/2008 | CA2674548A1 Novel n-(2-aminophenyl) benzamide derivative having urea structure |
| 07/03/2008 | CA2669916A1 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 07/02/2008 | EP1939291A2 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/02/2008 | EP1939203A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
| 07/02/2008 | EP1939202A1 Novel adenine compound |
| 07/02/2008 | EP1939201A1 Novel adenine compound |
| 07/02/2008 | EP1939200A1 Novel adenine compound |
| 07/02/2008 | EP1939199A1 Novel adenine compound |
| 07/02/2008 | EP1939198A1 Novel adenine compound |
| 07/02/2008 | EP1938839A1 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 07/02/2008 | EP1938837A1 Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid |
| 07/02/2008 | EP1938827A1 Novel inhibitor of vascular endothelial growth factor expression |
| 07/02/2008 | EP1938815A1 Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability |
| 07/02/2008 | EP1938799A1 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 07/02/2008 | EP1937295A2 Treatment of retinopathies using gfr 3 agonists |
| 07/02/2008 | EP1937290A1 Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| 07/02/2008 | EP1937281A2 Modulation of trpv expression levels |
| 07/02/2008 | EP1533313B1 Novel flavone c-glycoside derivatives and composition containing the derivatives |
| 07/02/2008 | EP1501808B1 Tachykinin receptor antagonists |
| 07/02/2008 | EP1427436B1 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 07/02/2008 | EP1115720B1 Novel n-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them |
| 07/02/2008 | CN101212960A Eye drop preparation comprising xanthan gum and terpenoid |
| 07/02/2008 | CN101210051A Anti-VEGF antibodies |
| 07/02/2008 | CN101210050A Anti-vegf antibodies |
| 07/02/2008 | CN101209322A 'Chuierbaoting' powder |
| 07/02/2008 | CN101209257A Medical use of baicalin and scutellarein derivatives |
| 07/02/2008 | CN101209241A Method for preparing medicine targeted controlled-release nano eyedrop |
| 07/02/2008 | CN100398653C Novel streptococcus antigens |